Lacroix André, Bourdeau Isabelle
Department of Medicine, Hôtel-Dieu du Centre Hospitalier de l'Université de Montréal, 3840 Saint-Urbain Street, Montreal, Quebec H2W 1T8, Canada.
Endocrinol Metab Clin North Am. 2005 Jun;34(2):441-58, x. doi: 10.1016/j.ecl.2005.01.004.
Corticotropin (ACTH)-independent bilateral macronodular adrenal hyperplasia (AIMAH) and primary pigmented nodular adrenocortical disease (PPNAD) are responsible for approximately 10% of adrenal Cushing's syndrome. AIMAH also can be present as subclinical bilateral incidentalomas in sporadic or familial forms. Diverse aberrant hormone receptors have been found to be implicated in the regulation of steroidogenesis and pathophysiology of AIMAH. PPNAD can be found alone or in the context of Carney complex, a multiple endocrine neoplasia syndrome. Additionally, it can be secondary to mutations of type 1 alpha-regulatory subunit of cAMP-dependent protein kinase A (PRKARIA). Strategies for the investigation and treatment of AIMAH and PPNAD are discussed.
促肾上腺皮质激素(ACTH)非依赖性双侧大结节性肾上腺增生(AIMAH)和原发性色素沉着结节性肾上腺皮质疾病(PPNAD)约占肾上腺库欣综合征的10%。AIMAH也可表现为散发性或家族性形式的亚临床双侧肾上腺偶发瘤。已发现多种异常激素受体与AIMAH的类固醇生成调节和病理生理学有关。PPNAD可单独出现,也可在卡尼复合征(一种多发性内分泌肿瘤综合征)的背景下出现。此外,它可能继发于环磷酸腺苷依赖性蛋白激酶A(PRKARIA)1α调节亚基的突变。本文讨论了AIMAH和PPNAD的调查及治疗策略。